Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Personalisierte Therapie beim Lungenkarzinom (S. 14–19)
Susann Stephan-Falkenau, Thomas Mairinger

  1.  TNM Klassifikation Maligner Tumoren. Wittekind C. Wiley-VCH, 8. Auflage 2017
  2. The 2015 WHO classification of lung tumors. Travis WD. Pathologe. 2014 Nov; 35 Suppl 2:188
  3. Prognostic considerations of the new World Health Organization classification of lung adenocarcinoma. Borczuk AC. Eur Respir Rev. 2016 Dec; 25(142): 364–71
  4. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, Meric-Bernstam F, Eterovic AK, Shaw KR, Mills GB, Gershenwald JE, Radvanyi LG, Hwu P, Futreal PA, Gibbons DL, Lazar AJ, Bernatchez C, Davies MA, Woodman SE.  BMC Med. 2016 Oct 25; 14(1): 168
  5. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Roh W, Chen PL, Reuben A, Spencer CN, Prieto PA, Miller JP, Gopalakrishnan V, Wang F, Cooper ZA, Reddy SM, Gumbs C, Little L, Chang Q, Chen WS, Wani K, De Macedo MP, Chen E, Austin-Breneman JL, Jiang H, Roszik J, Tetzlaff MT, Davies MA, Gershenwald JE, Tawbi H, Lazar AJ, Hwu P, Hwu WJ, Diab A, Glitza IC, Patel SP, Woodman SE, Amaria RN, Prieto VG, Hu J, Sharma P, Allison JP, Chin L, Zhang J, Wargo JA, Futreal PA. Sci Transl Med. 2017 Mar 1; 9(379). pii: eaah3560. doi:10.1126/scitranslmed.aah3560. Erratum in: Sci Transl Med. 2017 Apr 12; 9(385): PMID:28251903
  6. www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-kleinzellig-sclc/@@view/html/index.html
  7. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB.Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30132-2
  8. IASLC Atlas of ALK and ROS1 Testing in Lung Cancer. Ming Sound Tsao, Fred R Hirsch and Yasushi Yatabe (Eds). IASLC Publication, 2nd Edition 2017
  9. ROS1-Translocations in Non-Small Cell Lung Cancer. Warth A, Weichert W, Reck M, Reinmuth N.Pneumologie. 2015 Aug; 69(8): 477–82
  10. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options. Lazzari C, Spitaleri G, Catania C, Barberis M, Noberasco C, Santarpia M, Delmonte A, Toffalorio F, Conforti F, De Pas TM. Crit Rev Oncol Hematol. 2014 Mar; 89(3): 358–65
  11. Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations. Wang J, Wang B, Chu H, Yao Y.Onco Targets Ther. 2016 Jun 22; 9: 3711–26
  12. EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib. Saxon JA1, Sholl LM2, Jänne PA3. J Thorac Oncol. 2017 Jan 11. pii: S1556-0864(17)30011-4. doi:10.1016/j.jtho.2017.01.006. [Epub ahead of print]
  13. Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non-Small Cell Lung Cancer. Castellanos E1, Feld E1, Horn L2. J Thorac Oncol. 2017 Apr; 12(4): 612–23 doi: 10.1016/j.jtho.2016.12.014. Epub 2016 Dec 23
  14. Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Kobayashi Y1, Azuma K2, Nagai H3, Kim YH3, Togashi Y4,5, Sesumi Y1, Chiba M1, Shimoji M1, Sato K1, Tomizawa K1, Takemoto T1, Nishio K5, Mitsudomi T6. Mol Cancer Ther. 2017 Feb; 16(2): 357–64. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2
  15. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients. Nomizo T1, Ozasa H1, Tsuji T1, Funazo T1, Yasuda Y1, Yoshida H1, Yagi Y1, Sakamori Y1, Nagai H1, Hirai T1, Kim YH1. Sci Rep. 2017 Mar 23; 7: 45124. doi: 10.1038/srep45124
  16. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. Remon J1, Pardo N2, Martinez-Martí A3, Cedrés S4, Navarro A5, Martinez de Castro AM3, Felip E6. Lung Cancer. 2017 Apr; 106: 70 –75. doi: 10.1016/j.lungcan.2017.02.002. Epub 2017 Feb 6
  17. Diagnostic PD-L1 immunohistochemistry in NSCLC, results of the first German harmonization trial. AH. Scheel, M Dietel, LC. Heukamp, et al. ASCO Poster 2016 #3028
  18. Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy. Baik CS, Myall NJ, Wakelee HA. Oncologist. 2017 Jul; 22(7): 786–796. doi: 10.1634/theoncologist.2016-0458. Epub 2017 May 9. Review
  19. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. J Clin Oncol. 2017 May 1; 35(13): 1403–10. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13
  20. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values. Lee GD, Lee SE, Oh DY, Yu DB, Jeong HM, Kim J, Hong S, Jung HS, Oh E, Song JY, Lee MS, Kim M, Jung K, Kim J, Shin YK, Choi YL, Kim HR. J Thorac Oncol. 2017 Aug; 12(8): 1233–46. doi: 10.1016/j.jtho.2017.04.031. Epub 2017 May 10
  21. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung. Saffroy R, Fallet V, Girard N, Mazieres J, Sibilot DM, Lantuejoul S, Rouquette I, Thivolet-Bejui F, Vieira T, Antoine M, Cadranel J, Lemoine A, Wislez M. Oncotarget. 2017 Jun 27; 8(26): 42428–437. doi: 10.18632/oncotarget.164030
  22. www.onkopedia.com/de
  23. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma. DiBardino DM, Saqi A, Elvin JA, Greenbowe J, Suh JH, Miller VA, Ali SM, Stoopler M, Bulman WA. Clin Lung Cancer. 2016 Jun 8. pii: S1525-7304(16)30133-4
  24. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S; Hanshin-Saga Collaborative Cancer Study Group. Cancer Sci. 2016 Feb; 107(2): 162–7
  25. Pressemitteilung Bundesverband Deutscher Pathologen e.V. vom 19.6.2016: Liquid Biopsy – Neue Methode der Pathologie zur Tumorverlaufskontrolle. www.pathologie.de

Personalisierte Therapie bei hepatobiliären Tumoren (S. 20–26)
Arndt Vogel

  1. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33(6): 550–8
  2. Greten TF, Malek NP, Schmidt S, Arends J, Bartenstein P, Bechstein W, et al. [Diagnosis of and therapy for hepatocellular carcinoma]. Z Gastroenterol 2013; 51(11): 1269–326
  3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378–90
  4. Jackson R, Psarelli EE, Berhane S, Khan H, Johnson P. Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials. J Clin Oncol 2017; 35(6): 622–8
  5. Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol 2016
  6. Meyer T, Fox R, Ma YT, Ross PJ, James M, Strugess R, et al. TACE 2: A randomized placebo-controlled, double-blinded, phase III trial evaluating sorafenib in combination with transarterial chemoembolisation (TACE) in patients with unresectable hepatocellular carcinoma (HCC)Background. J Clin Oncol 2016; 34(15_suppl): 4018
  7. Kudo M, Han G, Finn RS, Poon RT, Blanc JF, Yan L, et al. Brivanib as adjuvant therapy to transarterial chemoembolization in patients with hepatocellular carcinoma: A randomized phase III trial. Hepatol 2014; 60(5): 1697–707
  8. Finn RS, Cheng A-L, Ikeda K, Kudo M, Tamai T, Dutcus CE, et al. A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. J Clin Oncol 2014; 32(15_suppl): 4153
  9. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389(10064): 56–66
  10. Zhu AX, Baron AD, Malfertheiner P, Kudo M, Kawazoe S, Pezet D, et al. Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score. JAMA Oncol 2016
  11. Rimassa L, Assenat E, Peck-Radosavljevic M, Zagonel V, Pracht M, Caremoli ER, et al. Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial. J Clin Oncol 2017; 35(15_suppl): 4000
  12. Melero I, Sangro B, Yau TC, Hsu C, Kudo M, Crocenzi TS, et al. Nivolumab dose escalation and expansion in patients with advanced hepatocellular carcinoma (HCC): The CheckMate 040 study. J Clin Oncol 2017; 35(4_suppl): 226
  13. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007; 245(5): 755–62
  14. Witzigmann H, Wiedmann M, Wittekind C, Mossner J, Hauss J. Therapeutical concepts and results for Klatskin tumors. Deutsches Arzteblatt international 2008; 105(9): 156–61
  15. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95(8): 1685–95
  16. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008; 15(10): 2787–94
  17. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol 2012; 30(16): 1934–40
  18. Schweitzer N, Weber T, Kirstein MM, Fischer M, Kratzel AM, Reineke-Plaass T, et al. The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis. J Cancer Res Clin Oncol 2017; 143(7): 1347–55
  19. Edeline J, Bonnetain F, Phelip JM, Watelet J, Hammel P, Joly J-P, et al. Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. J Clin Oncol 2017; 35(4_suppl): 225
  20. Primrose JN, Fox R, Palmer DH, Prasad R, Mirza D, Anthoney A, et al. Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study. J Clin Oncol 2017; 35
  21. 21. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362(14): 1273–81
  22. Malka D, Cervera P, Foulon S, Trarbach T, de la Fouchardiere C, Boucher E, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. Lancet Oncol 2014; 15(8): 819–28
  23. Lamarca A, Hubner RA, David Ryder W, Valle JW. Second-line chemotherapy in advanced biliary cancer: a systematic review. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014; 25(12): 2328–38
  24. Lowery MA, Abou-Alfa GK, Valle JW, Kelley RK, Goyal L, Shroff RT, et al. ClarIDHy: A phase 3, multicenter, randomized, double-blind study of AG-120 vs placebo in patients with an advanced cholangiocarcinoma with an IDH1 mutation. J Clin Oncol 2017; 35(15_suppl): 4142
  25. Mazzaferro V, El-Rayes BF, Cotsoglou C, Harris WP, Damjanov N, Masi G, et al. ARQ 087, an oral pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 genetic aberrations. J  Clin Oncol 2017; 35(15_suppl): 4017
  26. Bang YJ, Doi T, De Braud F, Piha-Paul S, Hollebecque A, Razak ARA, et al. Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028. Eur J Cancer 2015; 51: S112
  27. Le DT, Uram JN, Wang H, Kemberling H, Eyring A, Bartlett B, et al. PD-1 blockade in mismatch repair deficient non-colorectal gastrointestinal cancers. J Clin Oncol 2016; 34(4)

Systemische Therapie Neuroendokriner Neoplasien (S. 27–34)
Sebastian Noe

  1. Pavel, M., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017
  2. Pavel, M., et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology, 2016. 103(2): p. 172–85
  3. Pavel, M., et al. Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial. J Clin Endocrinol Metab, 2015. 100(4): p. 1511–9
  4. Kulke, M.H., et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer, 2014. 21(5): p. 705–14
  5. Falconi, M., et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology, 2012. 95(2): p. 120–34
  6. Falconi, M., et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2016. 103(2): p. 153–71
  7. van Adrichem, R.C., et al. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response? Neuroendocrinology, 2016. 103(5): p. 560–6
  8. Rinke, A., et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009. 27(28): p. 4656–63
  9. Caplin, M.E., et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med, 2014. 371(3): p. 224–33
  10. Strosberg, J., et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med, 2017. 376(2): p. 125–135
  11. Singh, S., et al. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology, 2017
  12. Garcia-Carbonero, R., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy. Neuroendocrinology, 2017.
  13. Yao, J.C., et al., Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med, 2011. 364(6): p. 514–23
  14. Raymond, E., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med, 2011. 364(6): p. 501–13
  15. Angelousi, A., et al. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments. Neuroendocrinology, 2017
  16. Velayoudom-Cephise, F.L., et al. Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer, 2013. 20(5): p. 649–57
  17. Hicks, R.J., et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues. Neuroendocrinology, 2017

UPDATE: Ovarialkarzinom (S. 41–46)
Anna-Maria Jäger, Barbara Schmalfeldt

  1. Harter P, Hauke J, Heitz F et al. Incidence of germline mutations in risk genes including BRCA1/2 in consecutive ovarian cancer (OC) patients (AGO TR-1). J Clin Oncol 2016; 34 (suppl): abstr. 5538
  2. Cancer Genome Atlas Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609–615
  3. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer. A report form the Australian Ovarian Cancer Stuy Group. J Clin Oncol 2012; 30: 2654–2663
  4. du Bois A, Reuss A, Pujade-Lauraine E et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancer de l’Ovaire (GINECO). Cancer 2009; 115: 1234–1244
  5. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspaglioni F, Lampe B, Landoni F, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Wagner UAG, duBois A. LION: Lymphadenectomy in ovarian neoplasm – A prospective randomized AGO study group led gynecologic intergroup trial. J Clin Oncol 35, 2017 (suppl;abstr 5500)
  6. Mahner S, Heitz F, Burges A, Reuss A, Kraemer B, Schmalfeldt B, Sehouli S, Lampe B, Schnelzer A, Wimberger P, Fotopoulou C, Guyon F, Lecuru F, Querleu D, Greggi S, Colombo N, Aletti GD, Harter P, duBois A. TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP 7). J Clin Oncol 35, 2017 (suppl; abstr TPS 5602) 
  7. Leitlinienprogramm Onkologie (DGK, DGGG, AWMF): S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren (Langversion). Version 2.0 – Oktober 2016. www.ago-online.de/fileadmin/downloads/leitlinien/ovar/2016/032-035-OLl_Ovarialkarzinom_2016-10.pdf
  8. du Bois A, Vergote I, Ferron G, Reuss A, Meier W, Greggi S, Jensen P, Selle F, Guyon F, Pomel C, Lecuru F, Zang R, Avall-Lunqvist E, Kim JW, Ponce J, Raspagliesi F, Ghaem-Maghami S, Reinthaller A, Harter P (PI , and Sehouli J. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: the interim analysis of AGO DESKTOP III / ENGOT ov20. J Clin Oncol 35, 2017 (suppl; abstr 5501)
  9. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with  platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA mutation status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861
  10. Pujade-Lauraine E, Lederman J, Penson R et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study. SGO 2017
  11. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012; 366: 1382–1392
  12. 12. Ledermann J, Harter P, Gourley C et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Oncol 2016; 17: 1579–1589
  13. Ledermann J, Harter P, Gourley C et al. Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer 2016; 115: 1313–1320
  14. Mirza MR et al. ENGOT-OV16/NOVA Trial: Niraparib maintenance therapy in patients with recurrent ovarian cancer. ESMO 2016; Abstr. LBA3_PR 
  15. Mirza MR et al. Niraparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer. N Engl J Med 2016; 375: 2154–2164
  16. Friedlander M, Gebski V, Gibbs E, Bloomfield R, Hilpert F, Wenzel LB, Joly F, Eek D, Rodrigues M et al. Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial. J Clin Oncol 35, 2017 (suppl, abstr 5507)

GESUNDHEITSÖKONOMIE: Gesundheitskompetenz (S. 50–51)
Nicole Ernstmann, Christoph Kowalski

  1.  Schaeffer, Doris; Berens, Eva-Maria; Vogt, Dominique (2017): Health Literacy in the German Population. In: Deutsches Arzteblatt international 114 (4), S. 53–60. DOI: 10.3238/arztebl.2017.0053
  2. Parker, R. (2000): Health literacy. A challenge for American patients and their health care providers. In: Health promotion international 15 (4), S. 277–283. DOI: 10.1093/heapro/15.4.277
  3. Hardie, Nancy A.; Kyanko, Kelly; Busch, Susan; Losasso, Anthony T.; Levin, Regina A. (2011): Health literacy and health care spending and utilization in a consumer-driven health plan. In: Journal of health communication 16 Suppl 3, S. 308–321. DOI: 10.1080/10810730.2011.604703
  4. Sørensen, Kristine; van den Broucke, Stephan; Fullam, James; Doyle, Gerardine; Pelikan, Jürgen; Slonska, Zofia; Brand, Helmut (2012): Health literacy and public health: a systematic review and integration of definitions and models. In: BMC public health 12, S. 80. DOI: 10.1186/1471-2458-12-80
  5. Koay, Kelvin; Schofield, Penelope; Jefford, Michael (2012): Importance of health literacy in oncology. In: Asia-Pacific journal of clinical oncology 8 (1), S. 14–23. DOI: 10.1111/j.1743-7563.2012.01522.x
  6. Shahid, Shaouli; Teng, Tiew-Hwa Katherine; Bessarab, Dawn; Aoun, Samar; Baxi, Siddhartha; Thompson, Sandra C. (2016): Factors contributing to delayed diagnosis of cancer among Aboriginal people in Australia. A qualitative study: Table 1. In: BMJ Open 6 (6), e010909. DOI: 10.1136/bmjopen-2015-010909
  7. Chapman, Lance W.; Ochoa, Alejandro; Tenconi, Francesca; Herman, Ariella (2015): Dermatologic health literacy in underserved communities: a case report of south Los Angeles middle schools. In: Dermatology online journal 21 (11)
  8. Thewes, Belinda; McCaffery, Kirsten; Davis, Esther; Garvey, Gail (2016): Insufficient evidence on health literacy amongst Indigenous people with cancer: a systematic literature review. In: Health promotion international. DOI: 10.1093/heapro/daw066
  9. Schmidt, Anna; Ernstmann, Nicole; Wesselmann, Simone; Pfaff, Holger; Wirtz, Markus; Kowalski, Christoph (2016): After initial treatment for primary breast cancer: information needs, health literacy, and the role of health care workers. In: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 24 (2), S. 563–571. DOI: 10.1007/s00520-015-2814-6
  10. Schmidt, Anna; Kowalski, Christoph; Pfaff, Holger; Wesselmann, Simone; Wirtz, Markus; Ernstmann, Nicole (2015): The Influence of Health Literacy on Information Needs Among Women Newly Diagnosed With Breast Cancer, With Special Reference to Employment Status. In: Journal of health communication 20 (10), S. 1177–1184. DOI: 10.1080/10810730.2015.1018626
  11. Halbach, Sarah Maria; Enders, Anna; Kowalski, Christoph; Pförtner, Timo-Kolja; Pfaff, Holger; Wesselmann, Simone; Ernstmann, Nicole (2016): Health literacy and fear of cancer progression in elderly women newly diagnosed with breast cancer--A longitudinal analysis. In: Patient education and counseling 99 (5), S. 855–862. DOI: 10.1016/j.pec.2015.12.012
  12. Zamora, P.; Riese, C.; Borges, U.; Baumann, W.; Schmitz, S. (2014): Patientenkompetenz in der oralen Krebstherapie (PACOCT). In: Forum 29 (1), S. 42–45. DOI: 10.1007/s12312-013-1085-8